AIMS: Part I: to establish the dose and appropriate application site of capsaicin on the human forearm in order to produce a robust and reproducible dermal blood flow (DBF) response. Part II: to evaluate the within-subject arm-to-arm and period-to-period reproducibility. METHODS: Both parts consisted of two study visits. In part I, placebo and 100, 300 and 1000 microg capsaicin were applied at four predefined sites on the volar surface of both forearms. Placebo and capsaicin doses were randomized and balanced by site between subjects. Changes in DBF were assessed by laser Doppler perfusion imaging up to 60 min after capsaicin application. In part II, only 1000 microg capsaicin was applied on the proximal forearm and changes in DBF assessed up to 30 min (t(30)). DBF response was expressed as percent change from baseline +/- SD and the corresponding AUC(0-30). Reproducibility assessment included calculation of the concordance correlation coefficient (CCC). RESULTS: Part I (n = 12 subjects): compared with placebo, 300 and 1000 microg capsaicin increased DBF (P < 0.05) at all time points except at 10 min. This increase was reproducible at the two most proximal sites from the 30-min time point onwards when compared between arms (CCC >or= 0.8, i.e. substantial to almost perfect reproducibility). In part II (n = 11), t(30) averaged 390 +/- 120% and arm-to-arm reproducibility was almost perfect (CCC = 0.91) for AUC(0-30). CONCLUSIONS:Capsaicin induces a reproducible within-subject arm-to-arm increase in DBF. We provide a non-invasive pharmacodynamic model in humans to test antagonists of mediators involved in capsaicin-induced dermal vasodilation, including calcitonin gene-related peptide antagonists.
RCT Entities:
AIMS: Part I: to establish the dose and appropriate application site of capsaicin on the human forearm in order to produce a robust and reproducible dermal blood flow (DBF) response. Part II: to evaluate the within-subject arm-to-arm and period-to-period reproducibility. METHODS: Both parts consisted of two study visits. In part I, placebo and 100, 300 and 1000 microg capsaicin were applied at four predefined sites on the volar surface of both forearms. Placebo and capsaicin doses were randomized and balanced by site between subjects. Changes in DBF were assessed by laser Doppler perfusion imaging up to 60 min after capsaicin application. In part II, only 1000 microg capsaicin was applied on the proximal forearm and changes in DBF assessed up to 30 min (t(30)). DBF response was expressed as percent change from baseline +/- SD and the corresponding AUC(0-30). Reproducibility assessment included calculation of the concordance correlation coefficient (CCC). RESULTS: Part I (n = 12 subjects): compared with placebo, 300 and 1000 microg capsaicin increased DBF (P < 0.05) at all time points except at 10 min. This increase was reproducible at the two most proximal sites from the 30-min time point onwards when compared between arms (CCC >or= 0.8, i.e. substantial to almost perfect reproducibility). In part II (n = 11), t(30) averaged 390 +/- 120% and arm-to-arm reproducibility was almost perfect (CCC = 0.91) for AUC(0-30). CONCLUSIONS:Capsaicin induces a reproducible within-subject arm-to-arm increase in DBF. We provide a non-invasive pharmacodynamic model in humans to test antagonists of mediators involved in capsaicin-induced dermal vasodilation, including calcitonin gene-related peptide antagonists.
Authors: M Tominaga; M J Caterina; A B Malmberg; T A Rosen; H Gilbert; K Skinner; B E Raumann; A I Basbaum; D Julius Journal: Neuron Date: 1998-09 Impact factor: 17.173
Authors: A Veves; R Saouaf; V M Donaghue; C A Mullooly; J A Kistler; J M Giurini; E S Horton; R A Fielding Journal: Diabetes Date: 1997-11 Impact factor: 9.461
Authors: Chi-Chung Li; Steve Vermeersch; William S Denney; William P Kennedy; John Palcza; Adrianna Gipson; Tae H Han; Rebecca Blanchard; Inge De Lepeleire; Marleen Depré; M Gail Murphy; Kristien Van Dyck; Jan N de Hoon Journal: Br J Clin Pharmacol Date: 2015-05 Impact factor: 4.335
Authors: Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon Journal: Br J Clin Pharmacol Date: 2010-01 Impact factor: 4.335
Authors: L Buntinx; T Voets; B Morlion; L Vangeel; M Janssen; E Cornelissen; J Vriens; J de Hoon; E Levtchenko Journal: Sci Rep Date: 2016-10-13 Impact factor: 4.379
Authors: David Monteith; Emily C Collins; Corinne Vandermeulen; Anne Van Hecken; Eyas Raddad; Joel C Scherer; David Grayzel; Thomas J Schuetz; Jan de Hoon Journal: Front Pharmacol Date: 2017-10-17 Impact factor: 5.810
Authors: Thuy Vu; Peiming Ma; Jiyun Sunny Chen; Jan de Hoon; Anne Van Hecken; Lucy Yan; Liviawati Sutjandra Wu; Lisa Hamilton; Gabriel Vargas Journal: Pharm Res Date: 2017-06-07 Impact factor: 4.200
Authors: Prasarn Manitpisitkul; Michael Brandt; Christopher M Flores; Velga Kenigs; John A Moyer; Gary Romano; Kevin Shalayda; Arthur J Mayorga Journal: Pain Rep Date: 2016-10-30